Johan van Beek

Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Jan M. Van Nueten, P A Janssen, Johan van Beek et al. · Journal of Pharmacology and Experimental Therapeutics · 1981 · 524 citations

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Ludwig Kappos, Hans‐Peter Hartung, Mark S. Freedman et al. · The Lancet Neurology · 2014 · 325 citations

Neurological Disorder, Pain Medicine, Medicine +7

Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway

Julie Lotharius, Jeppe Falsig, Johan van Beek et al. · Journal of Neuroscience · 2005 · 262 citations · Full text

Progressive Degeneration, Mixed-lineage Kinase Pathway, Medicine +15

Disruption of Neurogenesis on Gestational Day 17 in the Rat Causes Behavioral Changes Relevant to Positive and Negative Schizophrenia Symptoms and Alters Amphetamine-Induced Dopamine Release in Nucleus Accumbens

Peter Flagstad, Arne Mørk, Birte Glenthøj et al. · Neuropsychopharmacology · 2004 · 210 citations · Full text

Neurobiological Mechanism, Developmental Biology, Gestational Day 17 +14

Neuroprotective properties of memantine in different <i>in vitro</i> and <i>in vivo</i> models of excitotoxicity

Christiane Volbracht, Johan van Beek, Changlian Zhu et al. · European Journal of Neuroscience · 2006 · 173 citations

Neonatal Hypoxia-ischemia, Experimental Pharmacology, Neuroinflammation +19